Literature DB >> 30735545

Development of novel lipidic particles for siRNA delivery that are highly effective after 12 months storage.

Daniel Clarke1, Adi Idris1, Nigel A J McMillan1.   

Abstract

Liposomes are versatile and well-proven as a means to deliver nucleic acids into cells. Most of the formulation procedures used are labour intensive and result in unstable end products. We have previously reported on the development of a simple, yet efficient, hydration-of-freeze-dried-matrix (HFDM) method to entrap siRNA within n class="Chemical">lipid particles. Here we show that the particles are stable up to 12 months after storage at room temperature (RT), 4°C or -20°C. While RT storage results inpan> changes inpan> particle size and polydispersity, gene silencinpan>g of all particles was similar to freshly prepared particles followinpan>g storage for 3, 6, 9 or 12 months at all temperatures. This is the first report of such long-term stability inpan> siRNA-loaded liposomes.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 30735545      PMCID: PMC6368384          DOI: 10.1371/journal.pone.0211954

Source DB:  PubMed          Journal:  PLoS One        ISSN: 1932-6203            Impact factor:   3.240


Introduction

Various methods for formulating n class="Chemical">polynucleotide-loaded PEGylated particles have been reported to date, inpan>cludinpan>g post-inpan>sertion [1], reverse-phase evaporation [2], detergent dialysis [3] and n class="Chemical">ethanol dialysis [4-6]. However, most of these methods, though effective, require relatively complicated and lengthy formulation procedures with the resulting particles suspended in an aqueous state. This has led to long term storage issues including aggregation and/or fusion of the particles [7, 8], hydrolysis of the lipids [7], and instability of siRNA nucleotides in an aqueous environment. Moreover, these formulations are also prone to be affected by stresses occurred during transport, such as agitation or temperature fluctuation [8, 9]. These problems, along with the significantly increased effort required for large-scale production of these particles using the existing formulation procedures has held back clinical development and adoption. To address these issues, we developed a novel method to formulate stable, siRNA-loaded, PEGylated n class="Chemical">lipid particles usinpan>g the hydration of freeze-dried matrix (HFDM) method[10]. This simple, yet-efficient, procedure results inpan> n class="Chemical">lipid particles that are have highly favourable characteristics for in vivo delivery. Indeed, these particles have been used for in vivo systemic delivery in animal models to target a range of cancer-related genes, which have resulted in significant tumour elimination and increased survival [11, 12]. HDFM lipoplexes have also been used to reduce gene expression in lung tissues [13], the peritoneal cavity via intraperitoneal delivery [14] and in the vaginal epithelia with the aid of a novel aliginate matrix to increase retention time [15]. The simple mixing of n class="Chemical">lipids (n class="Chemical">DOTAP, cholesterol and PEG2000-C16Ceramide–molar ratio of 45:45:10) dissolved in tert-butanol with nucleic acids dissolved in sucrose followed by freeze-drying and rehydration results in lipid particles that are isotonic and ready for direct in vivo injection. Particles are ~190nm in size with a polydispersity index of 0.32 and an overall charge of 45mV. The encapsulated siRNA was protected from serum [10] and show excellent pharmacokinetics with T1/2 z>40h compared to other systems such as galactosylated cationic liposomes (T1/2 z>1h)[16], PEGylated polyplexes (T1/2 z>1.5h)[17], or SNALPS (T1/2 z>6.5h)[18]. This represented an advance in lipid formulation of siRNA for in vivo use. As mentioned above, liposomes are prepared fresh for in vivo use as they aggregate, fuse or hydrolyse in aqueous solutions over time. As the HFDM method results in a dried matrix we postulated that these resulting lipoplexes would be highly stable over time. Indeed, our initial studies examined the longevity of the freeze-dried siRNA/n class="Chemical">lipid matrix stored at 4°C, or room temperature (RT), for 4 weeks and showed that silencinpan>g was still signpan>ificant at this time [10]. Here, we have extended these studies out to 12 months and looked at a range of different storage conditions. We examinpan>ed the physical characteristics of the particles and their ability to silence target genes inpan> vitro at various time poinpan>ts. Our data show that HFDM lipoplexes are highly stable and still active for inpan> vitro silencinpan>g even 12 months post-production. Such post-production longevity has never previously been reported and represents a signpan>ificant advance inpan> the field.

Materials and methods

Cells and siRNA

HeLa cells were originally obtained from the American Type Culture Collectionpan> (ATCC) and were cultured as described previously [19]. The siRNA used in this study was Lamin A/C siRNA [20] obtained from Genesearch (Shanghai, China). siGlo red (Dharmacon, Lafayette, CO) was used as a qualitative transfection indicator as transfection efficiency.

Liposome formulations

Lipoplexes were prepared by Hydration of Freeze-Dried Matrix (HFDM) method as described previously [10]. Required amounts of n class="Chemical">DOTAP, n class="Chemical">cholesterol and PEG2000- C16Ceramide were dissolved in 1 mL of tert-butanol at a molar ratio of 45:45:10. 40μg of siRNA was added to 1 mL of filtered sucrose solution before mixing with the lipid solution. The resultant formulation was then snap-frozen and freeze-dried overnight (ALPHA 1–2 LDplus, Martin Christ, Germany) at a condensing temperature of −80°C and pressure of less than 0.1 mbar. Distilled H2O was then added to the lyophilised product with gentle shaking. A Nitrogen/Phosphate (N/P) ratio of 4:1 was used for all formulations and three separate batches were made for each formulation condition (n = 3). The final product contained 40μg siRNA in 300μL isotonic sucrose solution.

Particle characterisation

Size, polydispersity and zeta potential of the resultant lipoplexes were measured using a Zetasizer Nano ZS (Malvern Instruments, Malvern, UK) following appropriate dilution in distilled n class="Chemical">water. Measuremenpan>ts were carried out at room temperature (RT), 4°C and -20°C with 10 runpan>s per measuremenpan>t unpan>dertakenpan>.

siRNA entrapment efficiency

siRNA entrapment efficiencies were determined using the Quant-iT PicoGreen reagent (Invitrogen, California USA) as previously described [10].

Lipoplex cell uptake analysis

Cells were forward-transfected with 40μM of n class="Chemical">siGlo red. Cell uptake efficienpan>cy was assessed by flow cytometry 24h post-transfectionpan> onpan> a BD LSR FORTESSA cell analyser (BD bioscienpan>ce, San Jose, CA).

In vitro siRNA transfection

In vitro siRNA transfection of liposome-complexed siRNA was performed as previously described [10]. n class="CellLine">HeLa cells were seeded the day before the transfection experiment at a density of 75,000 cells per well inpan> a 6 well plate. A finpan>al concentration of 40 nM liposome-entrapped siRNA suspended inpan> n class="Chemical">primocin-free complete media was then added to each well. siRNAs were left on cells for 8 h, and cells were then incubated in primocin-containing media for 3 days at 37°C. The level of gene knockdown was determined by qPCR analysis and percentage of knockdown efficiency calculated as previously described [21].

qPCR

Extract of RNA, cDNA generation, and qPCR were carried out as described previously [19]. Real time primers used: Lamin A/C forward 5’-TGGAGATGATCCCTTGCTGA-3’, Lamin A/C reverse 5’-GCATGGCCACTTCTTCCCA-3’, β-actin forward 5’-AGCCTCGCCTTTGCCGA-3’and β-actin reverse 5’-CTGGTGCCTGGGGCG-3’.

Statistical analysis

All data were subjected to two-way An class="Chemical">NOVAs with Dunnett's post-hoc analyses using GraphPad Prism 7.

Results and discussion

We have previously showed that storage of our formulated lipoplexes for 1 month at RT and 4°C did not affect its physiochemical properties [10]. However, the physiochemical stability of the lipoplexes have never been tested outside these storage conditions. The stability of dried-state lipoplexes was investigated up to 12 months post-manufacture. Following formulation, the particles were stored at either RT, 4°C or -20°C. When compared to freshly-prepared lipoplexes, lipoplex powder stored at RT displayed greater variation in both size and n class="Gene">PDI upon rehydration, likely due to varyinpan>g humidity levels durinpan>g storage (Fig 1A and 1B). More importantly, no variation inpan> the surface charge (or zeta potential) of particles was observed when stored at any temperature over a 12-month period (Fig 1C), which is important for the stability of the particles and remainpan>inpan>g free from agglutinpan>ation when delivered inpan>to the bloodstream. In contrast to what we previously observed [10], the siRNA n class="Disease">entrapment efficiency did not fluctuate over time at different temperatures when compared to freshly-prepared lipoplexes, indicating the siRNA encapsulated in the lipoplexes were stable (Fig 1D). Overall, there was minimal effect of the storage time and temperature on the lipoplex physiochemical properties and the stability of the siRNA-loaded lipoplexes, with 4°Cand -20°C showing superior stability in terms of size, charge and size variation.
Fig 1

Lipoplex size, polydispersity, zeta potential and siRNA entrapment efficiency remains unchanged with long term storage at various temperatures except the lipoplex size and the polydispersity at room temperature.

(A) Size, (B) polydispersity and (C) zeta potential of the resultant lipoplex were measured using a Zetasizer Nano ZS following appropriate dilution in distilled water. Formulations were stored at either -20°C, 4°C or room temperature (RT) and 2 separate batches were made for each condition. (n = 2). (D) siRNA entrapment efficiencies were determined using the Quant-iT PicoGreen reagent. Tests were performed on freshly prepared lipoplex (F–Black shaded bars), and lipoplex stored at various temperatures for different lengths of time post manufacture. Bar graphs represent the mean and the error bars represent the standard deviation. **p value < 0.005, ***p value < 0.0005, ****p value <0.0001, two-way ANOVA using a Dunnett's post-hoc analysis against freshly prepared lipoplexes.

Lipoplex size, polydispersity, zeta potential and siRNA entrapment efficiency remains unchanged with long term storage at various temperatures except the lipoplex size and the polydispersity at room temperature.

(A) Size, (B) polydispersity and (C) zeta potential of the resultant lipoplex were measured using a Zetasizer Nano ZS following appropriate dilution in distilled n class="Chemical">water. Formulations were stored at either -20°C, 4°C or room temperature (RT) and 2 separate batches were made for each condition. (n = 2). (D) siRNA n class="Disease">entrapment efficiencies were determined using the Quant-iT PicoGreen reagent. Tests were performed on freshly prepared lipoplex (F–Black shaded bars), and lipoplex stored at various temperatures for different lengths of time post manufacture. Bar graphs represent the mean and the error bars represent the standard deviation. **p value < 0.005, ***p value < 0.0005, ****p value <0.0001, two-way ANOVA using a Dunnett's post-hoc analysis against freshly prepared lipoplexes. To assess whether storage time and temperature have any effect on the functional capability of the lipoplexes, the gene knockdown ability of siRNA-loaded lipoplexes was tested in vitro. In vitro cell uptake efficiency of lipoplexes stored over time at varying temperatures were comparable to that of freshly prepared lipoplexes (Fig 2A). Liposome powders were rehydrated at each time point, complexed with siRNAs and applied to n class="CellLine">HeLa cells to determinpan>e knpan>ockdown of the non-essential structural proteinpan>, n class="Gene">lamin A/C (LMNA). qPCR analysis revealed notable decrease of LMNA mRNA expression in HeLa cells treated with LMNA-specific siRNA compared to untransfected cells, irrespective of the storage conditions (Fig 2B). Furthermore, the knockdown efficiency (Fig 2C) at the mRNA level was comparable to that of freshly prepared liposomes suggesting that storage time and temperature have minimal effect on the gene-silencing efficiency of the siRNAs-complexed with lipoplexes. Although some liposome preparation groups had significantly different LMNA mRNA knockdown levels when compared to freshly prepared liposomes (Fig 2B and 2C), overall knockdown efficiencies for all preparations were well above 50% (Fig 2C).
Fig 2

siRNA-mediated target gene knockdown capability was maintained using lipoplexes stored at different temperatures over time in vitro.

(A) HeLa cells were treated with a final concentration of 40 nM of siGlo complexed into lipoplexes and incubated at 37°C for 24h before assessing siGlo uptake (%) by flow cytometry. Tests were performed on freshly prepared lipoplexes (F–Black shaded bars), and lipoplexes stored at various temperatures for different lengths of time post manufacture. Data is presented as percentage sum of fluorescence intensity. Bar graphs represent the mean and the error bars represent the standard deviation from three independent experiments. (B) HeLa cells were treated with a final concentration of 40 nM of Lamin A/C (LMNA) siRNA complexed into lipoplexes and incubated at 37°C for 3 days. Expression levels were calculated relative to non-transfected cells (control) by qPCR analysis and data presented as percentage of LMNA expression compared to control. β-actin was used as housekeeping control gene. (C) Percentage of knockdown efficiency was also determined as previously described [21]. Tests were performed on freshly prepared lipoplexes (F–Black shaded bars), and lipoplexes stored at various temperatures for different lengths of time post manufacture. Bar graphs represent the mean and the error bars represent the standard deviation from three independent experiments. **p value < 0.005, ***p value < 0.0005, ****p value <0.0001, two-way ANOVA using a Dunnett's post-hoc analysis against freshly prepared lipoplexes.

siRNA-mediated target gene knockdown capability was maintained using lipoplexes stored at different temperatures over time in vitro.

(A) n class="CellLine">HeLa cells were treated with a finpan>al concentration of 40 nM of n class="Chemical">siGlo complexed into lipoplexes and incubated at 37°C for 24h before assessing siGlo uptake (%) by flow cytometry. Tests were performed on freshly prepared lipoplexes (F–Black shaded bars), and lipoplexes stored at various temperatures for different lengths of time post manufacture. Data is presented as percentage sum of fluorescence intensity. Bar graphs represent the mean and the error bars represent the standard deviation from three independent experiments. (B) HeLa cells were treated with a final concentration of 40 nM of Lamin A/C (LMNA) siRNA complexed into lipoplexes and incubated at 37°C for 3 days. Expression levels were calculated relative to non-transfected cells (control) by qPCR analysis and data presented as percentage of LMNA expression compared to control. β-actin was used as housekeeping control gene. (C) Percentage of knockdown efficiency was also determined as previously described [21]. Tests were performed on freshly prepared lipoplexes (F–Black shaded bars), and lipoplexes stored at various temperatures for different lengths of time post manufacture. Bar graphs represent the mean and the error bars represent the standard deviation from three independent experiments. **p value < 0.005, ***p value < 0.0005, ****p value <0.0001, two-way ANOVA using a Dunnett's post-hoc analysis against freshly prepared lipoplexes. Previous studies have investigated the stability of dried-state liposomal preparations at different temperatures (i.e. 37°C to 60°C) over a 1-month period [22], this is the first study to investigate the physiochemical and functional effects of the prolonged storage of lipoplexes over a longer period of time (i.e. 12 months) and at lower temperatures. We developed this lyophilization procedure to ensure effective long-term storage of our lipoplexes, even at RT, as lipoplex suspensions are known to be unstable in aqueous suspension for long-term storage, especially with respect to hydrolysis and size stability. To date no data on the long term (up to 12 months) viability of siRNA-loaded liposomes have, to our knowledge, been published. There are longevity studies investigating traditional liposomes loaded with plasmid DNA. For example, an early study of unextruded liposomes made from DMRIE:DOPE complexed with plasmid DNA showed that when frozen as a aqueous solution they retained activity when thawed 12 months later [23]. More recently it was showed that DC- n class="Chemical">Cholesterol: DOPE liposomes loaded with plasmid DNA and freeze-dried were stable followinpan>g 3 months storage at RT and 40°C, although storage at 60°C resulted inpan> lost DNA structure [24]. Others have inpan>vestigated the stability of DNA n class="Chemical">oligonucleotide-loaded liposomes for antisense therapies, which changed size and lost ODN content over 12 months (RT) or 90 days (frozen)[25]. However, the functionality of these stored lipoplexes was not examined. Overall, we show that RT was inferior for storage, resulting in an increased particle size and polydispersity from 3 months onwards. Storage at 4°C and -20°C resulted in no changes in lipoplexes and silencing ability. Overall, HFDM liposomes exhibit excellent long-term storage characteristics.
  24 in total

1.  Small interfering RNA delivery to the liver by intravenous administration of galactosylated cationic liposomes in mice.

Authors:  Ayumi Sato; Motoki Takagi; Akira Shimamoto; Shigeru Kawakami; Mitsuru Hashida
Journal:  Biomaterials       Date:  2006-12-04       Impact factor: 12.479

2.  Development of a novel method for formulating stable siRNA-loaded lipid particles for in vivo use.

Authors:  Sherry Y Wu; Lisa N Putral; Mingtao Liang; Hsin-I Chang; Nigel M Davies; Nigel A J McMillan
Journal:  Pharm Res       Date:  2008-11-21       Impact factor: 4.200

3.  Stable and monodisperse lipoplex formulations for gene delivery.

Authors:  O Zelphati; C Nguyen; M Ferrari; J Felgner; Y Tsai; P L Felgner
Journal:  Gene Ther       Date:  1998-09       Impact factor: 5.250

4.  Aurora A Is Critical for Survival in HPV-Transformed Cervical Cancer.

Authors:  Brian Gabrielli; Fawzi Bokhari; Max V Ranall; Zay Yar Oo; Alexander J Stevenson; Weili Wang; Melanie Murrell; Mushfiq Shaikh; Sora Fallaha; Daniel Clarke; Madison Kelly; Karin Sedelies; Melinda Christensen; Sara McKee; Graham Leggatt; Paul Leo; Dubravka Skalamera; H Peter Soyer; Thomas J Gonda; Nigel A J McMillan
Journal:  Mol Cancer Ther       Date:  2015-10-29       Impact factor: 6.261

5.  A scalable, extrusion-free method for efficient liposomal encapsulation of plasmid DNA.

Authors:  Lloyd B Jeffs; Lorne R Palmer; Ellen G Ambegia; Cory Giesbrecht; Shannon Ewanick; Ian MacLachlan
Journal:  Pharm Res       Date:  2005-03       Impact factor: 4.200

6.  Stabilized plasmid-lipid particles: construction and characterization.

Authors:  J J Wheeler; L Palmer; M Ossanlou; I MacLachlan; R W Graham; Y P Zhang; M J Hope; P Scherrer; P R Cullis
Journal:  Gene Ther       Date:  1999-02       Impact factor: 5.250

7.  Systemic delivery of E6/7 siRNA using novel lipidic particles and its application with cisplatin in cervical cancer mouse models.

Authors:  S Y Wu; A Singhania; M Burgess; L N Putral; C Kirkpatrick; N M Davies; N A J McMillan
Journal:  Gene Ther       Date:  2010-08-12       Impact factor: 5.250

8.  Degradable polymer-coated gold nanoparticles for co-delivery of DNA and siRNA.

Authors:  Corey J Bishop; Stephany Y Tzeng; Jordan J Green
Journal:  Acta Biomater       Date:  2014-09-22       Impact factor: 8.947

9.  Stability of siRNA polyplexes from poly(ethylenimine) and poly(ethylenimine)-g-poly(ethylene glycol) under in vivo conditions: effects on pharmacokinetics and biodistribution measured by Fluorescence Fluctuation Spectroscopy and Single Photon Emission Computed Tomography (SPECT) imaging.

Authors:  Olivia M Merkel; Damiano Librizzi; Andreas Pfestroff; Tino Schurrat; Kevin Buyens; Niek N Sanders; Stefaan C De Smedt; Martin Béhé; Thomas Kissel
Journal:  J Control Release       Date:  2009-05-19       Impact factor: 9.776

10.  MUC13 protects colorectal cancer cells from death by activating the NF-κB pathway and is a potential therapeutic target.

Authors:  Y H Sheng; Y He; S Z Hasnain; R Wang; H Tong; D T Clarke; R Lourie; I Oancea; K Y Wong; J W Lumley; T H Florin; P Sutton; J D Hooper; N A McMillan; M A McGuckin
Journal:  Oncogene       Date:  2016-07-11       Impact factor: 9.867

View more
  1 in total

1.  Targeted Activation of Cystic Fibrosis Transmembrane Conductance Regulator.

Authors:  Olga Villamizar; Shafagh A Waters; Tristan Scott; Sheena Saayman; Nicole Grepo; Ryan Urak; Alicia Davis; Adam Jaffe; Kevin V Morris
Journal:  Mol Ther       Date:  2019-07-15       Impact factor: 11.454

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.